Cargando…
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell dysfunction in cancer, it is now well-accepted that interruption of PD-1/PD-L1 axes alone do...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621946/ https://www.ncbi.nlm.nih.gov/pubmed/31291985 http://dx.doi.org/10.1186/s40425-019-0611-3 |